{"filing":{"accession_number":"0001628280-26-052139","cik":"0001655759","ticker":"ARVN","company_name":"ARVINAS, INC.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"arvn-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1655759/000162828026052139/arvn-20260804.htm"},"events":[{"id":24016,"run_id":21723,"accession_number":"0001628280-26-052139","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Arvinas disclosed its financial results for Q2 2026 (quarter ended June 30, 2026) via press release furnished as Exhibit 99.1. The disclosure includes detailed financial metrics (cash position of $567.9 million, R\u0026D expenses of $52.6 million, revenue of $249.7 million), operational highlights (FDA approval of VEPPANU, licensing to Rigel Pharmaceuticals), and pipeline updates. This is a standard quarterly earnings release material to investors assessing the company's financial condition and progress.","company_name":"ARVINAS, INC.","ticker":"ARVN","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24398,"accession_number":"0001628280-26-052139","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Arvinas disclosed its financial results for Q2 2026 (quarter ended June 30, 2026) via press release furnished as Exhibit 99.1. The disclosure includes detailed financial metrics (cash position of $567.9 million, R\u0026D expenses of $52.6 million, revenue of $249.7 million), operational highlights (FDA approval of VEPPANU, licensing to Rigel Pharmaceuticals), and pipeline updates. This is a standard quarterly earnings release material to investors assessing the company's financial condition and progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:38:50.070681+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24398,"accession_number":"0001628280-26-052139","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Arvinas disclosed its financial results for Q2 2026 (quarter ended June 30, 2026) via press release furnished as Exhibit 99.1. The disclosure includes detailed financial metrics (cash position of $567.9 million, R\u0026D expenses of $52.6 million, revenue of $249.7 million), operational highlights (FDA approval of VEPPANU, licensing to Rigel Pharmaceuticals), and pipeline updates. This is a standard quarterly earnings release material to investors assessing the company's financial condition and progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:38:50.070681+00:00","company_name":"ARVINAS, INC.","ticker":"ARVN","filing_date":"2026-08-04"}]}